Machine learning with neuroimaging data to identify autism spectrum disorder: a systematic review and meta‑analysis
Autism spectrum disorder (ASD) is behaviourally defined by the presence of social communication deficits, and restricted repetitive behaviours.
Given the complexity and variation in the outward manifestations of ASD, neuroimaging studies provide crucial knowledge pertaining to this disease, including possible mechanisms underlying pathogenesis of the disorder.
The latest publication ‘Machine learning with neuroimaging data to identify autism spectrum disorder: asystematic review and meta‑analysis’, by Da‑Yea Song, Constantin‑Cristian Topriceanu, Denis C. Ilie‑Ablachim, Maria Kinali and Sotirios Bisdas, sheds light into the role of machine learning (ML) with neuroimaging data to provide a reliable classification of ASD.
Our meta-analysis results show the exciting prospect of applying ML in high quality brain MRI to diagnose ASD and highlight the issues required to address prior to any broad dissemination of the technique.
Full text available at https://rdcu.be/cvUbU
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.
Reach out to our expert team to discuss your development programs: firstname.lastname@example.org